| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 142.4 | 138.7 |
| Gross profit | 97.1 | 94.2 |
| Profit before tax | 6.2 | 4.7 |
| Net income | 6.0 | 3.2 |
| EPS (diluted, $ a share) | $0.08 | $0.05 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +89.8% |
|---|---|
| Revenue, year on year | +2.7% |
| Gross margin | 68.2% |
| Operating margin | 6.8% |
10-Q filed with the SEC, NASDAQ: BVS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Bioventus Inc.: key numbers
- Share price
- $10.46Close, Nov 16
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Bioventus Inc.
All →Bioventus Financial Results
Bioventus reported Q3 2026 worldwide revenue of $142.4 million, a 3% increase driven primarily by growth in its Pain Treatments business. The company achieved GAAP net income of $6.0 million and improved its diluted EPS to $0.08, while continuing to review potential strategic alternatives to maximize shareholder value.
- Term
- Q3 2026
“Bioventus delivered solid third-quarter results demonstrated by strong gross margin, operating cash flow and Adjusted EBITDA. We are encouraged by the underlying momentum across our key growth drivers and remain confident in our strategy, our portfolio and our ability to build Bioventus into a leading medtech company that delivers significant value for our shareholders, customers and employees.”
Rob Claypoole, Bioventus President and Chief Executive Officer